Monograph

J07BC02 - Hepatitis A, Inactivated, Whole Virus

Propably not porphyrinogenic

Rationale

Based on the pharmacokinetics of the hepatitis A, inactivated, whole virus vaccine, there are no conceivable porphyrinogenic effects.

Chemical description

Inactivated hepatitis A virus.

Therapeutic characteristics

The vaccine is indicated for the active immunization of adults and children over the age of 1against hepatitis A. It is administered by a single intramuscular injection. A booster dose is recommended after 6-12 months in order to obtain more persistent immunity.

Metabolism and pharmacokinetics

The hepatitis vaccine is not metabolized by the cytochrome P450 system.

IPNet drug reports

Uneventful use reported in 5 patients with acute porphyria.

References

#	Citation details	PMID
*	Government bodies
1.	Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
*	Summary of Product Characteristics
2.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Havrix.

Citation details

PMID

Government bodies

Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Havrix.

Similar drugs

Explore alternative drugs in similar therapeutic classes J07B / J07BC or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

Avaxim · Avaxim, suspensie voor injectie in een voorgevulde spuit 160U/0,5 ml · Havrix · Havrix 1440, suspensie voor injectie · Havrix Junior, suspensie voor injectie · Vaqta · Vaqta Adult, suspensie voor injectie 50 E/ml · Vaqta Junior, suspensie voor injectie 25 E/0,5 ml

Belgium

Avaxim · Avaxim 0.5 ml susp. inj. s.c./i.m. ser. préremplie · Havrix · Havrix 1440 susp. inj. s.c./i.m. flac. · Havrix 1440 susp. inj. s.c./i.m. ser. préremplie · Havrix Junior 720 susp. inj. s.c./i.m. flac. · Havrix Junior 720 susp. inj. s.c./i.m. ser. préremplie · Vaqta · Vaqta Junior 25 UI/0.5 ml susp. inj. s.c./i.m. flac. · Vaqta Junior 25 UI/0.5 ml susp. inj. s.c./i.m. ser. préremplie · Vaqta UI/ml s.c./i.m. · Vaqta 50 UI/ml susp. inj. s.c./i.m. flac. · Vaqta 50 UI/ml susp. inj. s.c./i.m. ser. préremplie

United Kingdom

Avaxim · Avaxim Junior vaccine suspension for injection 0.5ml pre-filled syringes · Avaxim vaccine · Avaxim vaccine suspension for injection 0.5ml pre-filled syringes · Epaxal Berna · Epaxal Berna injection 0.5ml pre-filled syringes · Epaxal vaccine · Epaxal vaccine emulsion for injection 0.5ml pre-filled syringes · Havrix · Havrix Monodose vaccine suspension for injection 1ml vials · Havrix Junior Monodose vaccine · Havrix Junior Monodose vaccine suspension for injection 0.5ml pre-filled syringes · Havrix Junior Monodose vaccine suspension for injection 0.5ml vials · Havrix Monodose vaccine · Havrix Monodose vaccine suspension for injection 1ml pre-filled syringes · VAQTA · VAQTA Adult vaccine suspension for injection 1ml pre-filled syringes · VAQTA Adult vaccine suspension for injection 1ml vials · VAQTA Paediatric vaccine · VAQTA Paediatric vaccine suspension for injection 0.5ml pre-filled syringes · VAQTA Paediatric vaccine suspension for injection 0.5ml vials · VAQTA vaccine · VAQTA vaccine suspension for injection 1ml pre-filled syringes

Denmark